anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
When patients are brought to the emergency room with a traumatic injury to the spinal cord, the road to recovery is long and uncertain. In minutes, their lives have been irreversibly altered. Time will tell if the paralysis to the limbs is permanent or if some degree of mobility or sensation can be reacquired. To many patients, the first weeks feel almost unreal. They find themselves in a state of shock, and feelings of uncertainty and loss of control are dominating. Spinal cord injuries are treated in multiple specialized hospital units. Each unit is accountable for providing the best possible treatment within their area of expertise. While continuity in care has been a hot research topic for the past 20 years, few studies provide empirical data on patients' perspectives on long-term hospital treatments. This study examines how patients with tetraplegia experience continuity in care when they journey across multiple hospital units over the course of several months. This paper is based on a study of patient pathways for patients with tetraplegia caused by high spinal cord injuries. Semi-structured interviews were conducted with nine patients, seven next of kin and thirteen healthcare professionals in Copenhagen University Hospital. Data from the interviews were analyzed using patient journey mapping, to uncover variations in patients' experience during various stages of their admission. The study finds that patients are struggling to maintain a sense of control over their life as they continuously engage in negotiations of perceptions of their body, of the physical surroundings and of their perception of time and the future. The study concludes that health care professionals should be mindful of these key themes to support the patients' empowerment and active participation during recovery.
A placebo looks exactly like the study drug but contains no active ingredients. It is used to learn if the effects seen are truly from the study drug. Participants receive placebo solution matching aldafermin (NGM282) given by subcutaneous injection once daily for 28 days.
OBJECTIVE: Sudden unexpected death in epilepsy (SUDEP) is a serious threat to individuals with intractable epilepsies, contributing to premature mortality. Understanding the elusive pathophysiological mechanisms of SUDEP, especially in cases without observable terminal events, remains a crucial area for investigation. This study aimed to shed light on the burden of epileptiform activity preceding SUDEP by utilizing an automated electronic seizure diary derived from a sensing-enabled thalamic deep brain stimulator (DBS).
METHODS: Herein, we present the case of a 57-year-old man afflicted with intractable multifocal epilepsy secondary to cortical dysplasia and encephalomalacia resulting from severe traumatic brain injury. Despite an initial successful resection and subsequent resurgence of seizures necessitating DBS treatment, the patient tragically succumbed to SUDEP.
RESULTS: In-depth analysis of the patient's electronic seizure diary, complemented by data from the sensing-enabled DBS, unveiled a terminal electrographic seizure. Notably, we observed a significant increase in power within specific frequency bands recorded from the thalamus preceding the terminal event. Furthermore, these heightened band power events displayed a discernible temporal clustering pattern, primarily manifesting during specific morning and evening hours. An autopsy conclusively confirmed the diagnosis of definite SUDEP.
INTERPRETATION: This unique case report underscores the feasibility of harnessing thalamic DBS sensing capabilities to monitor seizure burden and, potentially, to tailor interventions aimed at reducing seizure frequency and associated mortality risks.
An extraction method of avenanthramides, a spray and a preparation method thereof, which relate to the field of dermatitis treatment. A method for extracting avenanthramides comprises: extracting oat bran with a mixed solution of 1, 2-pentanediol and 1, 2-hexanediol at 50-70 deg.C for 1-3h, purifying the coarse extract with macroporous resin, and concentrating. The method can effectively extract avenanthramide. A spray is prepared from raw materials including the first main material including avenanthramide, 1, 2-pentanediol, 1, 2-hexanediol and dimethyl glycyrrhizinate, the second main material and adjuvants. The second main material comprises allantoin and water. The adjuvants include sodium hyaluronate, 1, 2-hexanediol and water. The spray adopts avenanthramides as main active ingredients, has the effect of repairing irritant dermatitis, and is natural and free of toxic and side effects.
Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
The invention relates to a nano-gold-coated layered double hydroxide composite material and its preparation method and use. The composite material has a core-shell structure and comprises double hydroxide particles coated with nano-gold particles, the average particle size of the nano-gold particles is less than 5nm, and the particle size of the double hydroxide particles is in a range of 20-200nm. The nano-gold-coated layered double hydroxide composite material can be used for drug delivery. Compared with the existing double hydroxide composite material, the nano-gold-coated layered double hydroxide composite material has pH sensitivity, high drug load and internal field circularity. The surface of the nano-gold-coated layered double hydroxide composite material can be subjected to positive and negative modification, be connected to a ligand and an antibody, and be subjected to amination, carboxylation and formylation. The nano-gold-coated layered double hydroxide composite material can be used as a drug carrier, realizes targeting and slow release in vivo, and improves drug in-vivo cycle time, a drug utilization degree and drug targeting effects.
The layer structure comprises a carrier substrate (100), active areas (101) that are spaced apart from each other and are applied to the carrier substrate, and a semipermeable outer layer (103) deposited or formed on the substrate and the active areas. The active areas contain an active ingredient. Each of the areas completely is completely surrounded by non-drug occupied intermediate areas (102) of the carrier substrate. The semi-permeable outer layer is directly or indirectly applied on the non-drug occupied intermediate areas on the substrate. The layer structure comprises a carrier substrate (100), active areas (101) that are spaced apart from each other and are applied to the carrier substrate, and a semipermeable outer layer (103) deposited or formed on the substrate and the active areas. The active areas contain an active ingredient. Each of the areas completely is completely surrounded by non-drug occupied intermediate areas (102) of the carrier substrate. The semi-permeable outer layer is directly or indirectly applied on the non-drug occupied intermediate areas on the substrate. Each of the active areas is enclosed around sides and from a top of the semi-permeable outer layer so that forming agent is deposited. The drug passes or diffuses to the outside through the semipermeable outer layer. The active areas are applied in the form of a repetitive pattern on the carrier substrate, and are separated by the non-drug intermediate areas. Each of the active regions is further completely covered by the semi-permeable coating layer. The semi-permeable outer layer covers the non-drug occupied intermediate areas of the substrate. The semipermeable outer layer comprises a polypropylene layer. The support substrate is \ adhered to the active ingredient and the semi-permeable outer layer. The semi-permeable outer layer has a thickness of 30 nm to 10mu m. The active areas have a thickness of 2 mm and a maximum diameter of 3 mm. The thickness of the semipermeable coating layer is selected so that the desired permeability of the semipermeable coating layer is achieved and a desired rate of diffusion of at least one drug through the semipermeable layer is achieved. A width of the non-drug occupied intermediate areas between adjacent active areas is selected so large that a reliable adhesion of the semi-permeable layer is around to ensure an active substance area. The active areas are sized so that the active ingredient particles are sufficiently small and harmless. The carrier substrate has recesses into which the active substance is introduced. Independent claims are included for: (1) an art bladder; (2) a catheter; and (3) a method for patterning a layer structure.
Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
Clinical care provided by geriatricians. Each participant will see the geriatrician at baseline and 6 months. In addition, they will receive the Otago Exercise Program, an individualized and home-based program of progressive strength and balance training exercises delivered by a physical therapist.
OBJECTIVE: Postoperative fasting following thoracoscopic surgery can cause intense thirst and oral discomfort. However, there is currently no research on ultraearly oral hydration (UEOH) in middle-aged or elderly patients after thoracoscopic surgery. The aim of this study was to investigate the effectiveness and safety of UEOH for improving oral discomfort after thoracoscopic surgery.
METHODS: This single-center prospective double-blind randomized controlled trial was conducted from April 2022 to November 2023. A total of 64 middle-aged and elderly patients who underwent the first thoracoscopic surgery on the day were enrolled at our institution. Postoperatively, in the Postanesthesia Care Unit (PACU), patients were randomly assigned at a 1:1 ratio to either the UEOH group or the standard care (SC) group. The primary outcome was the patient's thirst score at 6 h after surgery. Secondary outcomes included the incidence of postoperative oral discomfort; pain scores; the occurrence of adverse reactions such as nausea, vomiting, regurgitation and aspiration; anxiety scores on the first postoperative day; the time to first flatus; and recovery satisfaction scores.
RESULTS: The demographic and surgical characteristics were similar between the two groups. Patients in the UEOH group had lower thirst scores 6 h after surgery than did those in the SC group(16.1 ± 6.70 vs. 78.4 ± 8.42, P < 0.01). The incidence of postoperative oral discomfort (P < 0.01), anxiety scores on the first postoperative day (P<0.05), and time to first flatus (P<0.05) were better in the UEOH group. Additionally, the incidences of adverse reactions, such as postoperative nausea, vomiting, regurgitation and aspiration, were similar between the two groups (P>0.05).
CONCLUSION: For middle-aged and elderly patients undergoing thoracoscopic surgery, the use of a modified UEOH protocol postoperatively can improve thirst and promote gastrointestinal recovery without increasing complications.
TRIAL REGISTRATION: This single-center, prospective, RCT has completed the registration of the Chinese Clinical Trial Center at 07/12/2023 with the registration number ChiCTR2300078425.
BACKGROUND: Multiple cranial neuropathies (MCN) are the dysfunction of 2 or more cranial nerves, simultaneously or sequentially. The most common causes are tumors, followed by vascular and traumatic causes, central nervous system infections and Guillain-Barré syndrome and its variants.
OBJECTIVE: To identify the radiological clinical profile of MCN in patients of a tertiary-care hospital.
MATERIAL AND METHODS: Observational, cross-sectional, retrospective and analytical study in patients of 18 years of age or older, with a diagnosis of MCN. It was used descriptive statistics, and normality curves were determined. To establish differences, it was used chi-squared or Student's t test with the statistical package SPSS, version 29.
RESULTS: 46 patients with a mean age 49 years (± 16) were studied. 29 (63%) were male. Findings in the magnetic resonance of the skull were normal in 34%; the reinforcement of the cavernous sinus in 26%. Non-infectious inflammatory was the most frequent etiology (43%). 83% of the inflammatory etiology presented improvement at discharge while those of non-inflammatory etiology were discharged without improvement (odds ratio [OR] 8, p 0.001). 87% had pain in their clinical picture unlike subjects with non-inflammatory etiology (OR 4, p < 0.01). 73% of the population with inflammatory etiology presented recurrence, and none of the subjects with a non- inflammatory cause (OR 0.5, p 0.022).
CONCLUSIONS: The most common presentation of MCN in our study was cavernous sinus syndrome or sphenoidal cleft, with a non-acute course. The possibility of documenting an inflammatory etiology impacts the risk of recurrence and improvement upon hospital discharge.
Genomic sequencing has emerged as a powerful tool with significant implications for patients and their relatives, however, empirical evidence suggests that effective dissemination of risk information within families remains a challenge. Policy responses to address this issue vary across countries, with Belgium notably lacking specific regulations governing nondisclosure of genetic risk. In this study, we conducted semi-structured interviews with clinicians from Belgian clinical genetics centers to gain insight into their perspectives on policy approaches to the disclosure of genetic risk within families. Using real-world examples of legislation and court rulings from France, Australia, and the UK, we explored clinician viewpoints on the roles and responsibilities of both patients and clinicians in the family communication process. Clinicians expressed confusion regarding what was legally permissible regarding contacting at-risk relatives. While there was a consensus among participants that patients have a responsibility to inform their at-risk relatives, participants were hesitant to support the legal enforcement of this duty. Clinicians mostly recognized some responsibility to at-risk relatives, but the extent of this responsibility was a subject of division. Our findings highlight the need for a comprehensive policy that clarifies the roles and responsibilities of clinicians and patients to inform at-risk relatives. Furthermore, the study underscores the practical challenges clinicians face in supporting patients through the complex process of family communication, suggesting a need for additional resources and the exploration of alternative approaches to communication.
NEW MATERIAL:The compound of formula I. USE:A therapeutic agent of allergic diseases. PREPARATION:The compound of formula I is produced by reacting 1,2- dihydro-2,2-dimethyl-4H-3,1-benzoxazin-4-one of formula II with a reactive functional derivative of 3,4-dimethoxycinnamic acid (e.g. acid chloride) in an inert solvent in the presence of a basic catalyst (e.g. triethylamine, pyridine or dimethylaminopyridine). The compound of formula II used as a starting raw material is a new substance which can be produced by reacting anthranilic acid with 2,2-dimethoxypropane in the presence of an acid catalyst (e.g. benzenesulfonic acid) optionally in an inert solvent.
Anthracyclines, such as doxorubicin (adriamycin), daunorubicin, or epirubicin, rank among the most effective agents in classical anticancer chemotherapy. However, cardiotoxicity remains the main limitation of their clinical use. Topoisomerase IIβ has recently been identified as a plausible target of anthracyclines in cardiomyocytes. We examined the putative topoisomerase IIβ selective agent XK469 as a potential cardioprotective and designed several new analogs. In our experiments, XK469 inhibited both topoisomerase isoforms (α and β) and did not induce topoisomerase II covalent complexes in isolated cardiomyocytes and HL-60, but induced proteasomal degradation of topoisomerase II in these cell types. The cardioprotective potential of XK469 was studied on rat neonatal cardiomyocytes, where dexrazoxane (ICRF-187), the only clinically approved cardioprotective, was effective. Initially, XK469 prevented daunorubicin-induced toxicity and p53 phosphorylation in cardiomyocytes. However, it only partially prevented the phosphorylation of H2AX and did not affect DNA damage measured by Comet Assay. It also did not compromise the daunorubicin antiproliferative effect in HL-60 leukemic cells. When administered to rabbits to evaluate its cardioprotective potential in vivo, XK469 failed to prevent the daunorubicin-induced cardiac toxicity in either acute or chronic settings. In the following in vitro analysis, we found that prolonged and continuous exposure of rat neonatal cardiomyocytes to XK469 led to significant toxicity. In conclusion, this study provides important evidence on the effects of XK469 and its combination with daunorubicin in clinically relevant doses in cardiomyocytes. Despite its promising characteristics, long-term treatments and in vivo experiments have not confirmed its cardioprotective potential.
Disclosed are immunogenic compositions containing a polysaccharide-sortase conjugate. The polysaccharide is an antigen, and the sortase is a carrier protein. The sortase is covalently linked to the polysaccharide antigen by a linker including a sortase recognition sequence. Also disclosed are immunogenic compositions containing a polysaccharide-protein conjugate, the conjugate containing a polysaccharide antigen and a carrier protein. The polysaccharide antigen is covalently linked to the carrier protein by a linker including a sortase recognition sequence and a polyglycine motif present at the N-terminus of the carrier protein. Also disclosed are pharmaceutical compositions containing the immunogenic composition and a pharmaceutically acceptable excipient, methods of making the immunogenic compositions, and methods of generating immune response in a subject using the pharmaceutical composition.
The invention relates to a water lily herbal gel high-foaming hand sanitizer, which is characterized by combining water lily herbal essence extract with a surfactant and by having the functions of gently cleaning skin, deeply nourishing skin, and repairing skin. The formula of the hand sanitizer comprises effective components of water lily herbal essence liquid, coconut oleyl alcohol polyoxyethylene ether sodium sulfate, coconut oil sulfobetaine, citric acid, water lily placenta gel, sodium chloride and PEG-6000, and the water lily herbal gel high-foaming hand sanitizer is prepared by a special process. The hand sanitizer in the invention contains natural water lily herbal plant essence. With the adoption of 3ml of original liquid of the hand sanitizer to rub the hands for 30s, dirt can be gently and effectively removed without causing skin degreasing during the rubbing process. The hand sanitizer can release antibacterial molecules to destroy bacterial cytomembrane and to make bacteria lose activity, and is suitable for daily cleaning of hand skin. The hand sanitizer has functions of nourishing and moistening the skin, preventing the wrinkles, improving skin metabolism, and the like after a period usage.
Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
This study investigates the impact of experienced contact on prejudiced attitudes towards individuals with intellectual disabilities (IDs), examining beliefs in a just world (BJW) and social dominance orientation (SDO) as potential serial mediators. Data were collected from 224 university students (M = 23.02, SD = 2.48). Path analysis modelling assessed the structural relationships between the study variables. The findings revealed that experienced contact was negatively and significantly associated with BJW and SDO. Additionally, BJW and SDO fully mediated the relationship between experienced contact and overt prejudice. These findings underscore the influence of individual differences on attitudes towards individuals with ID, establishing a crucial foundation for future research and the development of interventions aimed at reducing prejudice and discrimination.
In addition to performing home-based Pilates exercises described in arm 1, this group will also perform home-based cognitive rehabilitation exercises for 8 weeks and 3 sessions per week. The interval between each session is at least 48 hours and each session will take between 30 to 45 minutes. Cognitive rehabilitation exercises are in pen and paper and each session includes two exercises in the areas of planning, cognitive organization, cognitive flexibility and working memory. All exercises will be explained to the subjects by a cognitive rehabilitation specialist, and in addition, explanations of all the exercises in each session will be available for participants in the separate voices. During the intervention period, in addition to the Pilates specialist, the cognitive rehabilitation specialist contacts the group 2 participants on a weekly basis and monitors their rehabilitation exercises.
PURPOSE: Despite their similar clinical characteristics, appendiceal diverticulitis (AD) and acute appendicitis (AA) are pathologically distinct. This study compared the clinical features of AD and AA and identified relevant risk factors.
METHODS: Patients who underwent appendectomy with a preoperative diagnosis of either AD or AA were categorized based on histopathological findings. The two groups were compared in terms of various clinical factors.
RESULTS: Among the 854 patients included in the study, a histopathological evaluation revealed 49 and 805 cases of AD and AA, respectively. A univariate analysis demonstrated that AD was more prevalent than AA among older, taller, and heavier males. A multivariate analysis revealed that male sex, a white blood cell (WBC) count < 13.5 × 103/μL, an eosinophil count ≥ 0.4%, and a mean corpuscular volume (MCV) ≥ 91.6 fL were significant factors differentiating AD from AA. In addition, pathological AD emerged as an independent risk factor for abscess and/or perforation.
CONCLUSIONS: AD was associated with an older age, robust physique, and significant risk of abscess and/or perforation despite a low WBC count. In addition to imaging modalities, the preoperative factors of male sex, a WBC count < 13.5 × 103/μL, an eosinophil count ≥ 0.4%, and a MCV ≥ 91.6 fL may be useful for distinguishing AD from AA.